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RESUMO
Intervenção Coronária Percutânea Emergencial de 
Tronco de Coronária Esquerda Não-Protegido em 
Paciente com Transplante do Coração
A doença vascular do enxerto cardíaco é a principal causa 
de falência do enxerto e morte depois do primeiro ano após 
o transplante. O melhor tratamento para lesões de tronco de 
coronária esquerda não-protegido em corações transplantados 
ainda não está estabelecido. Descrevemos o caso de uma 
intervenção coronária percutânea emergencial de tronco de 
coronária esquerda não-protegido em coração transplantado 
após morte súbita revertida com sucesso em paciente que 
aguardava cirurgia de revascularização do miocárdio.
Descritores: Transplante de coração. Doença da artéria coro-
nariana. Angioplastia. Stents farmacológicos.
ABSTRACT
Cardiac allograft vasculopathy is the leading cause of graft 
failure and death after the first year of heart transplantation. 
The optimal therapy for unprotected left main coronary artery 
disease in transplanted hearts has not been established. We 
report a case of emergency unprotected left main percutaneous 
coronary intervention in a transplanted heart after an aborted 







Descriptors: Heart transplantation. Coronary artery disease. 
Angioplasty. Drug-eluting stents.
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C ardiac allograft vasculopathy is the leading cause of graft failure and death after the first year of transplantation. There is gradual increase in the 
prevalence of vasculopathy in these patients: 8% in one 
year, 32% in five years, and 43% in eight years. After 
detection of diffuse or multivessel disease, the risk of 
death or retransplantation is extremely high.1
Drug treatment has shown significant improvement 
in the prevention of cardiac allograft vasculopathy, and 
consists in the aggressive control of classic risk factors 
for cardiovascular disease and treatment of acute re-
jection and infection by cytomegalovirus. Therapeutic 
options include percutaneous coronary intervention 
(PCI), coronary artery bypass graft (CABG) surgery, or 
a new heart transplant.
CABG may not be the best option, as diffuse intimal 
involvement frequently occurs, affecting distal vessels. 
Furthermore, perioperative mortality rates range between 
40% and 80%, and graft patency rates in the long-term 
are unknown.2,3 A new heart transplant is hindered by 
the scarcity of donors and high perioperative mortality. 
The survival rate for patients who undergo repeat cardiac 
transplantation (75% in one year) is lower when com-
pared to the first procedure, and half of these patients 
develop recurrent cardiac allograft vasculopathy.2,3 For 
these two types of surgical reintervention, there is a 
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higher chance of complications associated with repeat 
sternotomy, due to mediastinal fibrosis and risk of infec-
tion related to immunosuppressive therapy.2,3
PCI also has limitations in cases of diffuse cardiac 
allograft vasculopathy; however, it can constitute the 
definite treatment in selected patients, and it is the 
best alternative in emergency cases. The present study 
reports a case of emergency unprotected left main 
percutaneous coronary intervention in a transplanted 
heart after a successfully reversed sudden death in a 
patient awaiting CABG surgery.
CASE REPORT
Female patient, 50 years-old, former smoker, dys-
lipidemic, with peripheral arterial failure, had a past 
history of CABG in 1993 and heart transplant in 2001, 
due to ischemic heart disease with heart failure classified 
as New York Heart Association (NYHA) functional class 
IV, and Canadian Cardiovascular Society (CCS) class 
IV angina. She used atenolol, losartan, amiodarone, 
acetylsalicylic acid (ASA), atorvastatin, deflazacort, cy-
closporine, mycophenolate, cilostazol, and omeprazole.
From September 2012 onwards, she began to no-
tice oppressive precordial discomfort chest pain and 
dyspnea on exertion, with progressive symptom wors-
ening. An echocardiogram performed in October 2012 
evidenced left ventricle with preserved dimensions and 
systolic function; ejection fraction of 59%; mild mitral 
regurgitation; dilated right ventricle, with moderate to 
severe dysfunction; moderate tricuspid regurgitation; 
and estimated pulmonary artery systolic pressure of 40 
mmHg. The changes found were the same observed in 
the echocardiography performed in 2006.
A subsequent cardiac catheterization showed 50% 
lesion in the distal portion of the left main coronary 
artery, 40% lesions in the proximal third, and 70% 
and 95% lesions in the distal third of the left anterior 
descending artery. The left circumflex artery showed 
only mild and diffuse parietal irregularities, and the right 
coronary artery showed a 30% lesion in its distal third. 
The left ventricle showed normal end-diastolic volume 
and contractile function. The mitral valve did not allow 
for regurgitation. The recorded pressures were 85/12 
mmHg in the left ventricle and 85/59 mmHg in the 
aorta. During the same procedure, three endomyocar-
dial fragments were removed, whose histopathological 
analysis showed subendocardial fibrosis and absence 
of signs of rejection. In the previous catheterization, 
performed in 2008, the coronary arteries and the left 
ventricle showed no changes, and the biopsy found 
no rejection.
Her case was discussed at a meeting with the 
cardiology, hemodynamics, and cardiovascular sur-
gery teams in November 2012. There were discordant 
opinions: the interventionists indicated PCI for the left 
main coronary artery lesion, whereas surgeons and 
clinicians preferred surgical treatment. As there was 
a predominance of the second option, the procedure 
was scheduled for January 2013.
On December 25th, 2012, the patient went into 
cardiorespiratory arrest in asystole, successfully reversed. 
Upon arriving at the emergency room, she was ventilated 
through an endotracheal tube and received fentanyl, 
midazolam, and dopamine through infusion pumps. Vital 
signs showed blood pressure of 106/60 mmHg, heart 
rate of 73 bpm, and 93% oxygen saturation. Segmental 
assessment showed isochoric and photoreactive pupils, 
rhythmic and muffled heart sounds with no murmurs, 
discrete crackling rales at the bases, abdomen without 
visceromegaly, lower limbs without edema and with 
good perfusion. The electrocardiogram showed no acute 
ischemic changes. Initial laboratory assessment showed 
the following significant changes: creatine phosphokinase 
(CPK) = 526 U/L (24 U/L to 170 U/L), creatine kinase 
– MB fraction (CK-MB) = 30.7 U/L (< 25 U/L), troponin 
= 0.18 mg/L (< 0.01 g/L), and D-dimer = 5,681.3 ng/mL 
(68 ng/mL to 494 ng/mL).
Due to the evolution with persistent hypotension, 
requiring start of noradrenaline infusion, the hemo-
dynamic team was called to perform an emergency 
catheterization. The procedure, performed through the 
femoral artery, was uneventful and showed a 60% lesion 
in the distal third of the left main coronary artery, 60% 
lesions in the proximal third, 70% and 95% lesions in 
the distal third of the left anterior descending artery, 
30% lesion in the proximal third of the left circum-
flex artery, and 40% lesions in the middle and distal 
thirds of the right coronary artery. There were no new 
segmental contractility alterations in the left ventricle 
(Figure 1). The recorded pressures were 172/14 mmHg 
in the left ventricle and 172/83 mmHg in the aorta, and 
the norepinephrine infusion velocity was reduced. An 
arteriography was performed to rule out the suspicion 
of pulmonary thromboembolism; no thrombus or areas 
of peripheral hypoperfusion were found. The pressure 
measured in the left main coronary artery was 48/21 
mmHg, with a mean of 31 mmHg.
Regarding the adjuvant medication, the patient had 
already received ASA 200 mg and clopidogrel 300 mg. 
The dose of heparin was completed to 100 U/kg intra-
venously, and one ampoule of isosorbide mononitrate 
was administered by intracoronary route. The therapeutic 
catheter chosen was a JL 3.5 8F. Moderate support 
guidewires with hydrophilic and non-hydrophilic tips 
were positioned, respectively, in the distal portions of the 
left anterior descending artery and of the left circumflex 
artery. Subsequently, a 4.0/33 mm everolimus-eluting 
stent was implanted at 12 atm, covering the left main 
coronary artery and the proximal left anterior descend-
ing artery lesions. The circumflex artery guidewire was 
then retreated and repositioned in its distal third, pen-
etrating the stent mesh. It was decided to post-dilate 
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the stent with a 4.0/20 mm compliant balloon at 16 
atm. A 3.0/10 mm compliant balloon was positioned 
at the left circumflex artery ostium and the procedure 
was finished with a kissing balloon, both inflated to 
10 atm, yielding satisfactory angiographic result (Figure 
2). PCI was not performed in the other left anterior 
descending artery lesions, as they were located in the 
distal third, in a fine-calibre segment.
At the end of the procedure, the patient was 
hypertensive, allowing for a gradual reduction in the 
norepinephrine dose, which was suspended on the next 
day. Markers of myocardial necrosis showed a slight 
increase, reaching maximum values on December 25th, 
2012 at the collection performed 3.5 hours after the PCI 
(CPK = 671 U/L and CK-MB = 48.1 U/L). The following 
samples showed a progressive decrease in these values.
Pneumonia was diagnosed on December 27th, 
and treatment with piperacillin and tazobactam was 
initiated. On the following day, the patient developed 
supraventricular tachycardia reversed with electrical car-
dioversion. On the same day, the patient once more had 
hypotension, requiring reintroduction of noradrenaline. 
There was progressive clinical and laboratory worsening, 
and the patient went into cardiac arrest with pulseless 
electrical activity on December 31st, 2012.
DISCUSSION
Cardiac allograft vasculopathy is not a single 
disease entity, but rather a set of combined changes 
characterized by intimal fibromuscular hyperplasia, 
atherosclerosis (accelerated, affecting both adults and 
children), and vasculitis (inflammation of one or more 
layers of the vessel wall). Moreover, the veins are 
Figure 1 – In A, B, C, and D, left coronary artery in left-anterior oblique, 
caudal right-anterior oblique, caudal left-anterior oblique, and cranial 
left-anterior oblique projections, respectively. In E, right coronary artery 
in cranial left-anterior oblique projection. In F, left ventricular systole 
in the right-anterior oblique projection.
Figure 2 – In A, stent implantation in left main coronary artery lesions 
and proximal left anterior descending artery. In B, stent post-dilation. 
In C, control angiography in caudal right anterior oblique projection. 
In D, kissing balloon. In E, the final result in caudal right anterior 
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also affected, making the use of the term arteriopathy 
inaccurate.4
The most significant change in cardiac allograft 
vasculopathy is the intimal fibromuscular hyperplasia. By 
definition, it consists in intimal thickening promoted by 
fibromuscular proliferation, and not by the formation of 
atheromas or inflammation. Atherosclerotic plaques tend 
to be eccentric, to affect proximal epicardial vessels and 
spare the intramyocardial arteries. Intimal fibromuscular 
hyperplasia tends to be circumferential and may involve 
diffusely large and small epicardial coronary arteries, as 
well as intramyocardial vessels. This pattern of diffuse 
involvement of small epicardial arteries appears to cause 
most of the arterial occlusions. The intramyocardial arter-
ies are affected in their medial or subepicardial portions, 
making it unlikely that the endomyocardial biopsy will 
obtain samples with the involved vessels. It is important 
to note that calcification, unlike atherosclerosis, is not a 
prominent finding in intimal fibromuscular hyperplasia, 
even in severely affected vessels.4
Many risk factors for the development of cardiac 
allograft vasculopathy have been identified: systemic 
arterial hypertension, diabetes mellitus, dyslipidemia, 
obesity, insulin resistance, infection by cytomegalovirus, 
specific serology for leukocyte antigens, donor’s age, 
donor’s brain death, and occurrence of cell or humoral 
rejection.5 Symptom onset may be insidious and, since the 
heart is denervated, patients often do not report angina. 
Its existence suggests myocardial reinnervation, which 
occurs in 10% to 30% of recipients in the long-term. 
Manifestations may include silent ischaemia, conges-
tive heart failure, ventricular arrhythmias, myocardial 
infarction, and sudden death.6,7
The diagnosis of cardiac allograft vasculopathy 
is hindered by silent ischemia and low sensitivity of 
non-invasive tests. Intravascular ultrasound (IVUS) is 
more sensitive than coronary angiography to detect 
early disease and allows for the evaluation of both 
the arterial lumen and vessel wall. However, only the 
proximal portions can be evaluated, which limits its 
role in cases of diffuse vasculopathy.8
 The best treatment for cardiac allograft vasculopathy 
has not been established, but there is evidence that 
myocardium revascularization procedures are effective 
in transplanted hearts with evidence of ischaemia and/or 
high-risk lesions. Patients free of these conditions have 
a good prognosis; however, those with diffuse disease 
with no possibility of revascularisation have unfavoura 
unfavorable ble evolution.3
In transplanted patients, PCI presents excellent 
angiographic success rates, ranging from 90% to 100%, 
rare complications, and restenosis rates with drug-
eluting stents between 9% and 19%, lower than those 
of bare-metal stents (which range between 18% and 
31%).7-12 It is also a good therapeutic option for patients 
with left main coronary artery lesions. An international 
retrospective multicenter registry included 21 transplant 
patients undergoing unprotected left main coronary artery 
PCI from 1997 to 2009. Of the total procedures, 13 
(62%) were elective and eight (38%) were emergency, 
of which three (14%) were in cardiogenic shock. Ten 
individuals (48%) had bifurcation lesions in the left main 
coronary artery. Angiographic success was attained in 
all patients, of whom 14 (67%) received drug-eluting 
stents. In a mean follow-up time of 4.9 ± 3.2 years, three 
patients (14 %) died, one patient (5%) had myocardial 
infarction, and four (19%) had restenosis requiring 
target-lesion revascularization. There were no cases of 
stent thrombosis. One individual (5%) was submitted 
to CABG and five (24%), to a new transplant.11
In a review totaling ten publications and 34 pa-
tients undergoing left main coronary artery PCI in the 
transplanted heart, including the publication mentioned 
in the previous paragraph, four subjects (11.8%) died 
within a mean follow-up of 43.1 ± 32.4 months. Con-
sidering that 12 participants (35.3 %) had distal lesions 
in the left main coronary artery and 18 (52.9%) received 
bare-metal stents, repeat revascularization with PCI or 
CABG was required in nine subjects (26.4%). At 60 
months, death- and revascularisation-free survival was 
66%.12 To the present date, most articles published on 
unprotected left main coronary artery PCI in patients 
undergoing cardiac transplantation consist in a limited 
number of case reports and small series of patients.11,12
In conclusion, PCI with drug-eluting stents is a 
therapeutic option for transplanted patients with un-
protected left main coronary artery lesions, especially 
in emergency cases, and can delay the need for a new 
heart transplant. The procedure is safe and has high 
rates of immediate success; however, the long-term 
evolution requires further studies.
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